Latest developments and future directions in dengue vaccines

Area of Science:

• * Tropical Medicine
• * Vaccinology
• * Infectious Diseases

Background:

• * Dengue fever, a mosquito-borne viral illness, poses a growing global health threat.
• * Current prevention relies on vector control, with no specific antiviral treatments available.
• * A tetravalent dengue vaccine is a high public health priority to combat the expanding disease.

Purpose of the Study:

• * To review the progress and challenges in developing a tetravalent dengue vaccine.
• * To highlight the current landscape of dengue vaccine candidates in clinical and preclinical development.

Main Methods:

• * Review of current dengue vaccine development efforts.
• * Analysis of various vaccine platforms and their clinical trial stages.
• * Examination of challenges specific to dengue virus vaccine design.

Main Results:

• * Significant increase in dengue vaccine development intensity over the past decade.
• * One live-attenuated tetravalent vaccine candidate has reached Phase III efficacy studies.
• * Multiple other vaccine types (live-attenuated, subunit, DNA, inactivated, virus-vectored, virus-like particle) are in earlier clinical or preclinical development.

Conclusions:

• * Dengue vaccine development is complex due to viral diversity and disease spectrum.
• * Several promising candidates are advancing, offering hope for future disease control.
• * Continued research and diverse technological approaches are essential for a successful dengue vaccine.